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Sporozoites are the infective stage of malaria parasites present in the salivary
glands ofAnopheles mosquitoes. An effective vaccineagainst sporozoites should
prevent infection and, together with the use of residual insecticides and chemo-
prophylactic agents, contribute to the control ofthe disease. Sporozoite vaccines
against Plasmodium falciparum, containing part or the entire repeat domain of
the circumsporozoite (CS) protein, have recently undergone their first clinical
trials in human volunteers (1, 2). The choice ofthis antigen was based mainly on
studies showing that in vitro incubation ofsporozoites with mAb to the repeated
subunit sequences of CS proteins abolished their infectivity. Moreover, passive
transfer ofthe mAb to the mammalian hosts before the inoculation ofsporozoites
protected them from malaria infection (reviewed in reference 3).
Left unanswered are important questions regarding the effectiveness of vac-
cines containing CS protein repeats, and the role ofantibody and Tcell effector
mechanisms in protection. These questions could only recently be approached
experimentally, when the CS gene of Plasmodium berghei, a rodent malaria
parasite, was cloned and the corresponding amino acid sequence was elucidated
(4). This sequence contains a central region with tandemly repeated amino acid
units, varying somewhat in composition, DPPPPNPPN' In competitive binding
assays the (DPPPPNPN)2D peptide was 30-50 times better at inhibiting the
interaction of an mAb (3D11) with P. berghei sporozoites than the alternative
form, the (DPAPPNAN)2D peptide (4). Because the mAb 3D11 neutralizes the
infectivity of sporozoites very effectively (5), we postulated that vaccination of
mice with synthetic peptides containing the (DPPPPNPN)2D sequence might
induce protective antibodies when coupled with an appropriate carrier. The
present experiments address this question in a rodent model.
Materials and Methods
Synthesis ofPeptides 17.1 and 17.2.
￿
A 17-mer peptide ofthe tandemly repeatingdomain
of P. berghei (DPPPPNPN)2, designated 17 .1, and the alternative sequence
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(DPAPPNAN)2D, designated 17.2, were synthesized as described (4). The peptides
containing a p-hydroxybenzydrylamine handle were released from the resin by treatment
with 10% methylamine in tetrahydrofuran: ETOH (1 :1, vol/vol) for 14 h at 18'C.
Synthesis and Characterization ofaPolymer ofPeptide 17.1.
￿
The synthesis of the peptide
17.1 on a multiple antigen peptide system (MAPS) was initiated on a Boc-,B-Ala-OCH2-
Pam-resin (6) on which successive Boc-Lys (BOZ) were coupled to give an MAPS with
eight-reactive amino ends. The synthesis of 17.1 on this hexadecavalent MAPS was similar
to the synthesis of the linear 17.1 peptide. The MAPS containing 17.1 was then liberated
by the low trifluorometasulfonic acid method (7), and purified by dialysis in decreasing
concentrations of urea. The MAPS 17 .1, with a calculated molecular weight of 16,698,
gave the correct molecular weight and a single band in SDS-gel electrophoresis. Analysis
of the purified MAPS 17.1 in C,H reverse-phase HPLC gave a broad peak.
Expression in Yeast and Purification of the P. berghei CS Protein.
￿
Expression, and
subsequent purification to homogeneity of the central repeat region and flanking se-
quences of the P. berghei CS protein were performed as in reference 8.
Coupling of Synthetic Peptides to Tetanus Toxoid (TT).
￿
The synthetic peptide 17 .1 was
crosslinked with TT using glutaraldehyde (GA) (9), or bisdiazobenzidine (BDB) (10).
Immunization andIndirect Immunofluorescence Assay(IFA).
￿
A/J mice were injected twice
with 50 Ag of the conjugates. The first dose was incorporated into CFA and 100 AI were
given intraperitoneally. For the booster, the antigen was dissolved in PBS and 100,1 was
administered intravenously 15 d later. Norway Brown rats were immunized with 100 kg
of the conjugate in CFA and received two intravenous boosters 15 and 35 d after priming.
An additional group of mice was immunized with X-irradiated sporozoites with two
biweekly intravenous injections of 1 .5 X 105 parasites. Immunofluorescence was per-
formed using fixed sporozoites (11).
Detection of Exoerythrocytic Liver Stages (EEF) of P. berghei by DNA Hybridization.
￿
Rats
were killed 44 h after challenge with sporozoites, and the liver DNA was purified. The
amount of parasite DNA was estimated as described (12).
Immunoradiometric (IRMA) and Competitive Binding Assays.
￿
Flexible polyvinyl-chloride
microtiter wells (No. 3911, Falcon Labware, Oxnard, CA) were coated with 20 JAI of 1
jug/ml of the recombinant protein of P. berghei, or the polymer of the 17.1 peptide. The
serum titrations were performed as described (9).
To compare the avidities of the antipeptide and antisporozoite antibodies for the
synthetic peptide and the recombinant protein, pools of serum samples obtained after the
last immunization were diluted in PBS-BSA to obtain similar concentrations of antibodies.
The serum samples were incubated for 1 h with the different inhibitors and an aliquot of
the mixtures deposited into antigen-coated wells. The results were expressed as percent
of the binding obtained with the same sera in the absence of inhibitors.
Results and Discussion
First, we studied the immunogenicity of the two main repeat sequence units
DPPPPNPN and DPAPPNAN when presented in the context of the native
molecule, that is, in mice immunized with irradiated P. berghei sporozoites. We
compared the ability of the peptides 17 .1 [(DPPPPNPN)2D] and 17 .2
[(DPAPPNAN)2D] to inhibit the binding of antibodies in the sera of these mice
with immobilized recombinant protein (sporozoite extracts were not used as
antigen because they contain mosquito-derived immunogens) . Peptide 17.1 was
a much better inhibitor: 40% inhibition was obtained with 25 Ag of 17 .1, while
400 ,ug/ml of 17 .2 were necessary to achieve a comparable result (not shown) .
Having selected 17.1 as the peptide to be included in the vaccine, we compared
the immunogenicity of two conjugates of 17.1 with TT, prepared with either
glutaraldehyde or bisdiazobenzidine as crosslinking agents. Groups of six A/J
mice were injected with the two conjugates and controls were immunized with
X-irradiated sporozoites. The sera obtained 10 d after the booster injection wereZAVALA ET AL.
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FIGURE 1 . Titration of anti-17.1-GA-
TT, anti-17.1-BDB-TT, and antisporo-
zoite antibodies using as antigen immo-
bilized P. berghei recombinant CS pro-
tein (A) or a synthetic polymer of the
17.1 peptide (B). Results of competitive
bindingassays comparing thebindingof
the different sera to the recombinant
protein, in the presence of increasing
concentrations of the synthetic peptide
17 .1 or the recombinant protein, are
shown in C and D, respectively. The
resultsshow that 17.1-BDB-TT is a bet-
ter immunogen than 17.1-GA-TT.
Higher levels of antibodies to the CS
protein were found in the sera of mice
injected with 17.1-BDB-TT (top panels),
and their specificity resembled more
closely that of antibodies to sporozoites
(bottom panels).
pooled, and the levels of antibodies were determined by an IRMA using as the
antigen the 17.1 polymer or the recombinant CS protein. The latter was chosen
because it was more likely to mimic the configuration ofthe native protein and
permit a better assessment of the quality of the antipeptide antibodies.
The highest levels of antibodies were found in the sera of mice immunized
with 17.1-BDB-TT. The results of the titrations of the other two serum pools
varied with the antigen used in the IRMA. With the CS protein as antigen,
higher levels of antibodies were detected in the antisporozoite antisera than in
anti-17.1-GA-TT antisera. The reverse was true when 17.1 was the antigen,
indicating that the antipeptide and antisporozoite antibodies recognize best the
homologous antigens (Fig. 1, A and B).
Next, we compared the binding avidities of the three pooled sera for the
recombinant CS protein by performing competitive inhibition assays, the inhib-
itors being either the 17.1 peptide or the recombinant CS protein (Fig. 1, C and
D, respectively). Both inhibitors were quite effective and there were no marked
differences in the slopes ofthe titration curves. However, more recombinant CS
protein was required to inhibit the antipeptide antibodies than the antisporozoite
antibodies. When the inhibitor was 17.1, the reverse was observed, that is, more
peptide was required to inhibit the antisporozoite antibodies. It appears, there-
fore, that theantipeptide antibodies have a higher binding avidity forthe peptide,
while the antisporozoite antibodies react better with the recombinant protein.
Close inspection of the titration curves nevertheless shows that the patterns of
inhibition of antibodies to 17.1-BDB-TT more closely resemble those of the
antisporozoite antibodies. Because 17.1-BDB-TT induced higher titers of anti-
bodies ofhigher avidity than 17.1-GA-TT, it was used as a vaccine.1594
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TABLE I
Amounts ofP. berghei DNA in the Liver ofImmunized and Control
Rats 44 h after Challenge with 105 Sporozoites
TABLE II
Protectionfrom Malaria Infection by P. berghei Sporozoites after
Immunization with a Synthetic Peptide Vaccine
The effects ofthe 17.1-BDB-TT vaccine on sporozoite infectivity were evalu-
ated using a specific DNA probe to measure the number of EEF developing in
the livers of rats challenged with a large number (105) of P. berghei sporozoites
(12). The mean titer of antibody in the serum of the rats of the experimental
group was 10,660 ± 3,771 . As shown in Table I, the livers contained 97% less
parasite DNA than those ofthe controls vaccinated with TT. No parasite DNA
was detected in the livers ofthree ofsix immunized rats.
To determine the degree of protection against malaria infection that this
vaccine would provide, we immunized A/J mice. After the first dose, the serum
titers of antibody against sporozoites were 1,635 ± 992; after the booster
injection, they rose to 26,000 ± 7,745. 15 d later, the mice were challenged
intravenously with 1,000 sporozoites. In two experiments, 87 and 75% of
vaccinated mice did not develop parasitemia, a degree of protection comparable
to that obtained by immunization with irradiated parasites (85%). All naive mice
and all mice immunized with TT developed parasitemia 4 to 5 d after the
challenge (Table II).
The T lymphocytes of the vaccinated mice did not proliferate after in vitro
incubation with the synthetic peptide 17.1, although there was a strong response
to both TT and 17.1-BDB-TT (data not shown). Furthermore, immunization of
this strain of mice with the monomer or a polymer of the synthetic repeat
Exp. lmmunogen Range IFA
Titers x 10'
Number
protected/
challenged
Percent
protection
1 17.1-BDB-tetanus toxoid 16-32 7/8 87
BDB-tetanus toxoid Neg 0/8 0
X-irradiated sporozoites 4-16 6/7 85
None Neg 0/5 0
2 17.1-BDB-tetanus toxoid 16-64 6/8 75
BDB-tetanus toxoid Neg 0/8 0
None Neg 0/5 0
lmmunogen Number
P. berghei
DNA in
liver
ng
Mean ± SD
Peptide 17.1 conjugated to tetanus 1 0.0
toxoid with bisdiazobenzidine 2 21 .0
3 13.3 6.2±8.8
4 0.0
5 3.4
6 0.0
Tetanus toxoid treated with bisdi- 7 192.0
azobenzidine 8 273.6
9 55.8 184.9±97.0
10 316.6
11 122.3
12 149.2ZAVALA ET AL.
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peptide, without the carrier protein, did not induce antibody production. These
results strongly suggestthathelper cellsofA/Jmicedo notrecognize the peptide,
and that their protective immunity was mediated solely by antibodies.
In short, active immunization with a synthetic peptide representing the repeat
domain ofa CS protein can induce high levels ofantibodies to the native protein,
and effectively protect against sporozoite-induced malaria infection. Using the
same experimental model, but with a different peptide vaccine formulation,
others reported only marginal protection with 500 P. berghei sporozoites (13).
The lower efficacy ofthat vaccine formulation might have been due to the use
of a repeat peptide containing the alanine substitutions, instead of
(DPPPPNPN)2D . Furthermore, in those studies glutaraldehyde was used for
coupling the peptide to the carrier protein. In our experiments, the levels and
avidity of antibodies to the native protein were consistently lower in mice
vaccinated with 17.1-GA-TT than in mice vaccinated with 17.1-BDB-TT. The
reasons for this are not clear except that with glutaraldehyde the peptide is
bound to the carrier through the NH2-terminal and with BDB through the
COOH-terminal handle. Striking effects ofthe orientation ofa synthetic peptide
on the immunogenicity and on the specificity of the induced antibodies have
been reported (14).
We conclude that protective immunity to sporozoites can be obtained exclu-
sively by antibodies to the repeats ofthe CS protein. A few volunteers had been
vaccinated with X-irradiated sporozoites, and recently a synthetic and a recom-
binant vaccine against P. falciparum containing a portion of the repeat domain
ofthe CS protein were tested in humans. In both instances, protection coincided
with the presence ofantisporozoite antibodies.
However, because sporozoites remain in circulation for a very short time
before entering the liver cells, antibody levels would have to be maintained at
sufficiently high levels to be fully protective. This may be difficult to achieve
with peptide or recombinant vaccines containing only repeats. The identification
of T cell epitopes in the CS polypeptide (or in other sporozoite-associated
proteins) would permit their inclusion in vaccines. Sensitized Tcells are a source
of IFN--y, which has a potent inhibitory effect on the liver stages of malaria
parasites (15). Vaccines that contain sporozoite-specific T cell epitopes might be
more advantageous because the antibody response would be boosted during
infection, and T cell-dependent killing mechanisms would be triggered.
Summary
A synthetic peptide, (DPPPPNPN)2D, representing a subunit of the repeat
domain of the Plasmodium berghei circumsporozoite protein, was conjugated to
tetanus toxoid using bisdiazobenzidine. Immunization of mice and rats with the
conjugate induced high serum titers of antibodies to the parasite, and most of
the animals were completely protected from malaria infection when challenged
with sporozoites.
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